Ge Long Hui·2025-08-18 23:48Group 1 - The company Rongchang Biopharmaceutical (09995.HK) has entered into a licensing agreement with Santen Pharmaceutical (China) Co., Ltd. for the RC28-E injection, granting Santen exclusive rights for development, production, and commercialization in Greater China and several Southeast Asian countries [1][2] - The agreement includes a non-refundable upfront payment of 250 million RMB, potential milestone payments up to 520 million RMB for development and regulatory achievements, and up to 525 million RMB for sales milestones, along with a tiered sales royalty based on product sales in the licensed territories [1] - The licensing agreement is set to take effect on August 18, 2025, and will remain in force unless terminated early according to its terms [1] Group 2 - The licensing agreement is expected to accelerate market access and patient coverage for RC28-E, significantly shortening the commercialization cycle and providing innovative solutions for the treatment of retinal diseases [2] - Santen Pharmaceutical, a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd., has over 130 years of experience in the ophthalmic field and is a leader in the global ophthalmic market, focusing on the development, production, and sale of ophthalmic drugs and medical devices [2]